secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2022-06-29T23:59:59+00:00
Accession:  0000886163-22-000097
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand appoints Jason Haas to Board of Directors, effective June 29, 2022
-------------------------------------------------------------------------

- Jason Haas appointed to Board and Audit Committee; brings 30+ years healthcare investment banking experience.
- Haas currently CFO of Syros Pharmaceuticals; previously Co-Head Americas Healthcare Banking at Barclays.
- Received 1,750 RSUs and options for 5,907 shares at $88.52, vesting over three years.
- Chairman Kozarich cites Haas' 10+ years as Ligand financial advisor; appointment ahead of OmniAb spin-off.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616322000097/0000886163-22-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616322000097/lgnd-20220629.htm
  HTML page:      https://secwatch.observer/filing/0000886163-22-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer